News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tau Therapeutics, LLC and National Cancer Institute Launch Phase Ib Clinical Trial in Brain Cancer



5/31/2012 10:02:41 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute’s Adult Brain Tumor Consortium (ABTC) using the company’s first product candidate mibefradil. The trial will introduce a new therapeutic approach to patients with recurrent high-grade glioma.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES